- Home
- Publications
- Publication Search
- Publication Details
Title
Stepping forward in antibody-drug conjugate development
Authors
Keywords
Antibody-drug conjugates (ADCs), Cancer therapy, Clinical research, Metabolism
Journal
PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 107917
Publisher
Elsevier BV
Online
2021-06-24
DOI
10.1016/j.pharmthera.2021.107917
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody Glycoengineering and Homogeneous Antibody‐Drug Conjugate Preparation
- (2021) Shino Manabe et al. CHEMICAL RECORD
- Antibody–Drug Conjugate Payloads; Study of Auristatin Derivatives
- (2020) Michinori Akaiwa et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- (2020) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation
- (2020) Yutaka Matsuda et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
- (2020) Jonathan Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Correcting the Side Effects of ADC Filtering in MR Image Reconstruction
- (2020) Carole Lazarus et al. JOURNAL OF MATHEMATICAL IMAGING AND VISION
- Macropinocytosis confers resistance to therapies targeting cancer anabolism
- (2020) Vaishali Jayashankar et al. Nature Communications
- Trastuzumab Deruxtecan: First Approval
- (2020) Susan J. Keam DRUGS
- First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
- (2020) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
- (2020) Hans C. Lee et al. LEUKEMIA
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates
- (2020) Xiaoyu Zhu et al. Journal of Pharmaceutical Analysis
- Cancer stromal targeting therapy to overcome the pitfall of EPR effect
- (2020) Yasuhiro Matsumura ADVANCED DRUG DELIVERY REVIEWS
- Antibody-Drug Conjugates: The New Frontier of Chemotherapy
- (2020) Sara Ponziani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Megapinosome: Morphological description of a novel organelle
- (2020) Andrea Bauer et al. JOURNAL OF STRUCTURAL BIOLOGY
- Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
- (2020) Aaron D. Goldberg et al. LEUKEMIA RESEARCH
- Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective
- (2020) David Dahlgren et al. MOLECULES
- A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma
- (2019) Sumanta K. Pal et al. CANCER
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
- (2019) Daniel P. Petrylak et al. PROSTATE
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
- (2019) A. Keith Stewart et al. Blood Cancer Journal
- Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer
- (2019) Jason B. White et al. mAbs
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
- (2019) Deaglan McHugh et al. INVESTIGATIONAL NEW DRUGS
- First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
- (2019) Ignacio Garrido-Laguna et al. INTERNATIONAL JOURNAL OF CANCER
- Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
- (2019) Alain Beck et al. Expert Review of Proteomics
- First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
- (2019) Christophe Massard et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
- (2019) Patrick A. Ott et al. CANCER
- Recent Chemical Approaches for Site‐specific Conjugation of Native Antibodies: Technologies toward Next Generation Antibody‐Drug Conjugates
- (2019) Kei Yamada et al. CHEMBIOCHEM
- A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
- (2019) Jeffrey P. Sharman et al. INVESTIGATIONAL NEW DRUGS
- Manipulation of cell-type selective antibody internalization by a guide-effector bispecific design
- (2019) Nam-Kyung Lee et al. MOLECULAR CANCER THERAPEUTICS
- Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy
- (2019) Jeffrey C. Kang et al. NATURE BIOTECHNOLOGY
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2019) John Y. Li et al. CANCER CELL
- Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
- (2019) Mark Rosenthal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON ‐1 Study
- (2019) Ajit Suri et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
- (2019) Sajad Yaghoubi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Antibody therapeutics and immunoregulation in cancer and autoimmune disease
- (2019) Masahiro Yasunaga SEMINARS IN CANCER BIOLOGY
- Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients
- (2019) David E. Gerber et al. CLINICAL CANCER RESEARCH
- Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)
- (2019) Kashif Haider et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
- (2019) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
- (2019) Hibiki Udagawa et al. LUNG CANCER
- First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
- (2019) Sung-Bae Kim et al. Targeted Oncology
- HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors
- (2019) Mark D. Pegram et al. CLINICAL CANCER RESEARCH
- Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
- (2019) Lisa M. Kopp et al. EUROPEAN JOURNAL OF CANCER
- PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
- (2019) Daniel P. Petrylak et al. PROSTATE
- An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
- (2019) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- (2019) David S. Hong et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
- (2019) Christine Alewine et al. CLINICAL CANCER RESEARCH
- Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
- (2019) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Towards personalized treatment for early stage HER2-positive breast cancer
- (2019) Kristina Goutsouliak et al. Nature Reviews Clinical Oncology
- Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
- (2018) S Banerjee et al. ANNALS OF ONCOLOGY
- Antibody–Drug Conjugates for Cancer Treatment
- (2018) John M. Lambert et al. Annual Review of Medicine
- Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
- (2018) Dian Su et al. BIOCONJUGATE CHEMISTRY
- Bispecific antibody based therapeutics: Strengths and challenges
- (2018) Archana Thakur et al. BLOOD REVIEWS
- Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
- (2018) Glenwood D. Goss et al. CANCER
- Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas
- (2018) John A Thompson et al. CLINICAL CANCER RESEARCH
- A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia
- (2018) Bruno C. Medeiros et al. Clinical Lymphoma Myeloma & Leukemia
- ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development
- (2018) M. Walles et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers
- (2018) L. Nathan Tumey et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
- (2018) Kathleen N Moore et al. Future Oncology
- A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
- (2018) Marek Trněný et al. HAEMATOLOGICA
- Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
- (2018) Anastasios Stathis et al. INVESTIGATIONAL NEW DRUGS
- A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
- (2018) Gentry T. King et al. INVESTIGATIONAL NEW DRUGS
- Characterization of an antibody-drug conjugate by hydrophilic interaction chromatography coupled to mass spectrometry
- (2018) Valentina D’Atri et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor
- (2018) Ryo Tsumura et al. JOURNAL OF CONTROLLED RELEASE
- Fate of Antibody-Drug Conjugates in Cancer Cells
- (2018) Cécile Chalouni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates
- (2018) Aditya V. Gandhi et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
- (2018) Katsuyuki Hotta et al. Journal of Thoracic Oncology
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps
- (2018) Kenneth R. Durbin et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of clathrin-mediated endocytosis
- (2018) Marko Kaksonen et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton
- (2018) Michel O. Steinmetz et al. TRENDS IN CELL BIOLOGY
- Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells
- (2018) Yuan-Chiang Chung et al. Scientific Reports
- A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
- (2018) Marek Trněný et al. HAEMATOLOGICA
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
- (2018) Sikander Ailawadhi et al. Clinical Lymphoma Myeloma & Leukemia
- Novel biomarkers in hepatocellular carcinoma
- (2018) Felice De Stefano et al. DIGESTIVE AND LIVER DISEASE
- Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
- (2018) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
- (2018) Tycel Phillips et al. INVESTIGATIONAL NEW DRUGS
- A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species
- (2018) Brian M. Maas et al. mAbs
- Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
- (2018) Marion Lepelley et al. Annals of Hepatology
- An automated microfluidic chemiluminescence immunoassay platform for quantitative detection of biomarkers
- (2018) Xiaoping Min et al. BIOMEDICAL MICRODEVICES
- Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
- (2018) Ursula A Matulonis et al. CLINICAL CANCER RESEARCH
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
- (2018) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
- (2018) John H. Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Brentuximab vedotin in T-cell lymphoma
- (2018) Carrie Van Der Weyden et al. Expert Review of Hematology
- Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
- (2017) Sergii Kolodych et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
- (2017) Nicolas Joubert et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
- (2017) Lainie P. Martin et al. GYNECOLOGIC ONCOLOGY
- Diversification of IgG effector functions
- (2017) Stylianos Bournazos et al. INTERNATIONAL IMMUNOLOGY
- Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
- (2017) Khaldoun Almhanna et al. INVESTIGATIONAL NEW DRUGS
- A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
- (2017) Khaldoun Almhanna et al. INVESTIGATIONAL NEW DRUGS
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
- (2017) Geoffrey I. Shapiro et al. INVESTIGATIONAL NEW DRUGS
- Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
- (2017) Efrat Dotan et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term direct visualization of passively transferred fluorophore-conjugated antibodies
- (2017) Jeffrey R. Schneider et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
- (2017) Dennis A Eichenauer et al. LANCET ONCOLOGY
- A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life
- (2017) Pernille Foged Jensen et al. MOLECULAR & CELLULAR PROTEOMICS
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
- (2017) Matthew Sung et al. MOLECULAR CANCER THERAPEUTICS
- Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
- (2017) Julian Andreev et al. MOLECULAR CANCER THERAPEUTICS
- Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using Cysteine Insertion
- (2017) Nazzareno Dimasi et al. MOLECULAR PHARMACEUTICS
- Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
- (2017) Paul Malik et al. PHARMACEUTICAL RESEARCH
- Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
- (2017) Florentina Kubizek et al. PROTEIN AND PEPTIDE LETTERS
- Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
- (2017) Muhammad Kalim et al. Drug Design Development and Therapy
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Enzyme-linked immunosorbent assay (ELISA): the basics
- (2016) Karishma Shah et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- Trastuzumab cardiotoxicity: from clinical trials to experimental studies
- (2016) Balazs T Nemeth et al. BRITISH JOURNAL OF PHARMACOLOGY
- Humanized Mouse Xenograft Models: Narrowing the Tumor–Microenvironment Gap
- (2016) J. Jason Morton et al. CANCER RESEARCH
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2016) Ranjana H. Advani et al. CLINICAL CANCER RESEARCH
- Abnormal Corneal Lesions Induced by Trastuzumab Emtansine
- (2016) Mayuko Tsuda et al. CORNEA
- Engineering antibody therapeutics
- (2016) Mark L Chiu et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Megapinocytosis: a novel endocytic pathway
- (2016) Andrea Bauer et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
- (2016) Rémy Gébleux et al. INTERNATIONAL JOURNAL OF CANCER
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I − Optimization of separation conditions
- (2016) Morgan Sarrut et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species
- (2016) Mélissa Excoffier et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques
- (2016) Tao Chen et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
- (2016) Nancy L. Bartlett et al. LEUKEMIA & LYMPHOMA
- Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89 Zr-ImmunoPET
- (2016) Anton G.T. Terwisscha van Scheltinga et al. MOLECULAR CANCER THERAPEUTICS
- Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry
- (2016) Christian Lanshoeft et al. RAPID COMMUNICATIONS IN MASS SPECTROMETRY
- Biomarkers along the continuum of care in lung cancer
- (2016) Stefan Holdenrieder SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
- Diagnostic, prognostic and therapeutic role of CD30 in lymphoma
- (2016) John Matthew R. Pierce et al. Expert Review of Hematology
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
- (2015) Jessica R. McCombs et al. AAPS Journal
- Antibody Drug Conjugates: Nonclinical Safety Considerations
- (2015) Mary Jane Masson Hinrichs et al. AAPS Journal
- Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
- (2015) Gregory S. Hamilton BIOLOGICALS
- Current methods for the synthesis of homogeneous antibody–drug conjugates
- (2015) Alicja M. Sochaj et al. BIOTECHNOLOGY ADVANCES
- Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
- (2015) Samantha Gromek et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Tentative identification of new metabolites of cnidilin by liquid chromatography–mass spectrometry
- (2015) Haoli Huo et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
- (2015) R. Gebleux et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Targeting Notch, Hedgehog and Wnt pathways in cancer stem cells: clinical update
- (2015) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
- (2015) Shi Xu PHARMACEUTICAL RESEARCH
- An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates
- (2015) Janice A. Lansita et al. PHARMACEUTICAL RESEARCH
- Quantitative whole-body autoradiography: past, present and future
- (2015) Andrew McEwen et al. Bioanalysis
- In vivo biotransformations of antibody–drug conjugates
- (2015) L Nathan Tumey et al. Bioanalysis
- Cancer vaccines
- (2015) L. H. Butterfield BMJ-British Medical Journal
- Cancer vaccines
- (2015) L. H. Butterfield BMJ-British Medical Journal
- Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy
- (2015) Magdalena Dorywalska et al. PLoS One
- Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality
- (2014) M. Benjamin Hock et al. AAPS Journal
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Antibody-drug conjugates: an emerging modality for the treatment of cancer
- (2014) Mauricio Leal et al. Annals of the New York Academy of Sciences
- Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
- (2014) George Badescu et al. BIOCONJUGATE CHEMISTRY
- Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody
- (2014) William M Pardridge Expert Opinion on Drug Delivery
- Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
- (2014) Yuan Wang et al. JOURNAL OF DRUG TARGETING
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
- (2014) Amrita V. Kamath et al. PHARMACEUTICAL RESEARCH
- Clathrin-Independent Pathways of Endocytosis
- (2014) S. Mayor et al. Cold Spring Harbor Perspectives in Biology
- Initiation of clathrin-mediated endocytosis: All you need is two?
- (2013) Laura E. Swan BIOESSAYS
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
- (2013) Brian Gurbaxani et al. MOLECULAR IMMUNOLOGY
- Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology
- (2013) Stanley A. Roberts et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates
- (2012) Diego A. Gianolio et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake
- (2012) Boris Gorovits et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
- (2012) Ben-Quan Shen et al. CURRENT DRUG METABOLISM
- Small molecule drugs – optimizing DNA damaging agent-based therapeutics
- (2012) John A Hartley et al. CURRENT OPINION IN PHARMACOLOGY
- Monoclonal antibody therapeutics: history and future
- (2012) Nicholas APS Buss et al. CURRENT OPINION IN PHARMACOLOGY
- Antibody–drug conjugates – a perfect synergy
- (2012) John R Adair et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Antibody–drug conjugates: Basic concepts, examples and future perspectives
- (2012) Giulio Casi et al. JOURNAL OF CONTROLLED RELEASE
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
- (2012) J. Y. Axup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots
- (2011) Masahiro Yasunaga et al. CANCER SCIENCE
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Investigational antibody drug conjugates for solid tumors
- (2011) Puja Sapra et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Identification of Amino Acid Residues Responsible for the Release of Free Drug from an Antibody–Drug Conjugate Utilizing Lysine–Succinimidyl Ester Chemistry
- (2011) Hung-Wei Chih et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4
- (2011) Daniela Bumbaca et al. mAbs
- In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
- (2011) X. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Development of a high performance liquid chromatography method and a liquid chromatography–tandem mass spectrometry method with pressurized liquid extraction for simultaneous quantification and confirmation of cyromazine, melamine and its metabolites in foods of animal origin
- (2010) Huan Yu et al. ANALYTICA CHIMICA ACTA
- Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes
- (2010) Aditya A. Wakankar et al. BIOCONJUGATE CHEMISTRY
- Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents
- (2010) Scott C. Jeffrey et al. ACS Medicinal Chemistry Letters
- Multilayers enzyme-coated carbon nanotubes as biolabel for ultrasensitive chemiluminescence immunoassay of cancer biomarker
- (2009) Sai Bi et al. BIOSENSORS & BIOELECTRONICS
- Immunoglobulin G4: an odd antibody
- (2009) R. C. Aalberse et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Promising tumor-associated antigens for future prostate cancer therapy
- (2009) Yong Li et al. MEDICINAL RESEARCH REVIEWS
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Tumor Stroma as a Target in Cancer
- (2008) F. Ahmed et al. CURRENT CANCER DRUG TARGETS
- Structural classification of CDR-H3 revisited: A lesson in antibody modeling
- (2008) Daisuke Kuroda et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now